Pregnancy in acromegaly patients treated with pegvisomant
- 458 Downloads
To summarize all available data on pregnancy outcome of acromegaly patients exposed to the growth hormone receptor antagonist pegvisomant (PEGV) during pregnancy as present in the Pfizer’s Global Safety Database. Pfizer’s Global Safety Database contains adverse event data obtained from the following sources: spontaneous reports, health authorities, Pfizer-sponsored post-marketing surveillance program (ACROSTUDY), customer engagement programs, and clinical studies, reported regardless of outcome. The safety database was searched up to 10th March 2014. From the 35 pregnancy cases, 27 involved maternal [mean age (range) 33.3 years (23–41) and 8 paternal (33.7 years (32–38)] PEGV exposure. Two female patients were reported with two pregnancy cases each. Fetal outcome was normal in 14 (4 paternal) of the 18 reported as live birth, while 4 cases (1 paternal) did not specify the birth outcome. At conception, PEGV mean dose (range) was 15.3 mg/d (4.3–30). In 3 cases of maternal exposure of the 18 cases reporting live birth, PEGV was continued throughout the pregnancy in a dose of 12.1 mg/d (10–15). In 5 cases (all maternal) an elective termination of the pregnancy was performed with no reported fetal abnormalities, 2 cases (maternal) reported a non-PEGV-related spontaneous abortion and in 1 maternal case an ectopic pregnancy occurred. In 9 cases (3 paternal), the fetal outcome was not reported. Three women reported gestational diabetes; one woman continued PEGV treatment during pregnancy. Although the number of reported pregnancies with exposure to PEGV is very small, the presented data reflect the largest series of data available to date and do not suggest adverse consequences of PEGV on pregnancy outcome. Nevertheless, it should be stressed that PEGV should not be used during pregnancy unless absolutely necessary.
KeywordsAcromegaly Pregnancy Pegvisomant Treatment Complications
ACROSTUDY is sponsored by Pfizer Inc.
AJvdL, received honoraria from Pfizer as member of the ACROSTUDY Strategic Advisory Board, CCH, RG, JH, A-CÅ, and PJ are permanent employees of Pfizer, MK-H was a full time employee at Pfizer Health AB when the work was done but now is an affiliate at the Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden.The authors were not paid for their contribution to this manuscript.
- 1.G.G. Brigss, R.K. Freeman, S.J. Yaffe, Drugs in Pregnancy and Lactation, 8th edn. (Lippincott Williams & Wilkins, Philadelphia, 2011)Google Scholar
- 2.P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, E.V. Dimaraki, P.M. Stewart, K.E. Friend, M.L. Vance, G.M. Besser, J.A. Scarlett, M.O. Thorner, C. Parkinson, A. Klibanski, J.S. Powell, A.L. Barkan, M.C. Sheppard, M. Malsonado, D.R. Rose, D.R. Clemmons, G. Johannsson, B.A. Bengtsson, S. Stavrou, D.L. Kleinberg, D.M. Cook, L.S. Phillips, M. Bidlingmaier, C.J. Strasburger, S. Hackett, K. Zib, W.F. Bennett, R.J. Davis, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342(16), 1171–1177 (2000). doi: 10.1056/NEJM200004203421604 PubMedCrossRefGoogle Scholar
- 3.A.J. van der Lely, R.K. Hutson, P.J. Trainer, G.M. Besser, A.L. Barkan, L. Katznelson, A. Klibanski, V. Herman-Bonert, S. Melmed, M.L. Vance, P.U. Freda, P.M. Stewart, K.E. Friend, D.R. Clemmons, G. Johannsson, S. Stavrou, D.M. Cook, L.S. Phillips, C.J. Strasburger, S. Hackett, K.A. Zib, R.J. Davis, J.A. Scarlett, M.O. Thorner, Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358(9295), 1754–1759 (2001)PubMedCrossRefGoogle Scholar
- 4.A.J. van der Lely, B.M. Biller, T. Brue, M. Buchfelder, E. Ghigo, R. Gomez, J. Hey-Hadavi, F. Lundgren, N. Rajicic, C.J. Strasburger, S.M. Webb, M. Koltowska-Haggstrom, Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J. Clin. Endocrinol. Metab. 97(5), 1589–1597 (2012). doi: 10.1210/jc.2011-2508 PubMedCrossRefGoogle Scholar
- 6.P. Wiesli, C. Zwimpfer, J. Zapf, C. Schmid, Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess. Acta Obstet. Gynecol. Scand. 85(8), 900–905 (2006). doi: 10.1080/00016340600676532 PubMedCrossRefGoogle Scholar
- 8.S. Cheng, L. Grasso, J.A. Martinez-Orozco, R. Al-Agha, R. Pivonello, A. Colao, S. Ezzat, Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature. Clin. Endocrinol. (Oxford) 76(2), 264–271 (2012). doi: 10.1111/j.1365-2265.2011.04180.x CrossRefGoogle Scholar
- 10.P. Maffei, G. Tamagno, G.B. Nardelli, C. Videau, C. Menegazzo, G. Milan, A. Calcagno, C. Martini, R. Vettor, J. Epelbaum, N. Sicolo, Effects of octreotide exposure during pregnancy in acromegaly. Clin. Endocrinol. (Oxford) 72(5), 668–677 (2010). doi: 10.1111/j.1365-2265.2009.03706.x CrossRefGoogle Scholar